ADAM10 mediates shedding of carbonic anhydrase IX ectodomain non‑redundantly to ADAM17.
ADAM10
ADAM17
cancer
carbonic anhydrase IX
ectodomain shedding
internalization
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
08
08
2022
accepted:
31
10
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
20
12
2022
Statut:
ppublish
Résumé
Carbonic anhydrase IX (CA IX) is a transmembrane enzyme participating in adaptive responses of tumors to hypoxia and acidosis. CA IX regulates pH, facilitates metabolic reprogramming, and supports migration, invasion and metastasis of cancer cells. Extracellular domain (ECD) of CA IX can be shed to medium and body fluids by a disintegrin and metalloproteinase (ADAM) 17. Here we show for the first time that CA IX ECD shedding can be also executed by ADAM10, a close relative of ADAM17, via an overlapping cleavage site in the stalk region of CA IX connecting its exofacial catalytic site with the transmembrane region. This finding is supported by biochemical evidence using recombinant human ADAM10 protein, colocalization of ADAM10 with CA IX, ectopic expression of a dominant‑negative mutant of ADAM10 and RNA interference‑mediated suppression of ADAM10. Induction of the CA IX ECD cleavage with ADAM17 and/or ADAM10 activators revealed their additive effect. Similarly, additive effect was observed with an ADAM17‑inhibiting antibody and an ADAM10‑preferential inhibitor GI254023X. These data indicated that ADAM10 is a CA IX sheddase acting on CA IX non‑redundantly to ADAM17.
Identifiants
pubmed: 36524367
doi: 10.3892/or.2022.8464
pii: 27
pmc: PMC9813547
doi:
pii:
Substances chimiques
ADAM Proteins
EC 3.4.24.-
ADAM10 Protein
EC 3.4.24.81
ADAM10 protein, human
EC 3.4.24.81
ADAM17 Protein
EC 3.4.24.86
ADAM17 protein, human
EC 3.4.24.86
Carbonic Anhydrase IX
EC 4.2.1.1
Membrane Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Biol Chem. 2009 Jul 24;284(30):20299-310
pubmed: 19458084
Curr Alzheimer Res. 2012 Feb;9(2):140-56
pubmed: 21605031
Nat Methods. 2006 Dec;3(12):995-1000
pubmed: 17072308
Cancer Biol Ther. 2016 Aug 2;17(8):870-80
pubmed: 27115328
Semin Cancer Biol. 2015 Apr;31:52-64
pubmed: 25117006
Br J Cancer. 2020 May;122(11):1590-1603
pubmed: 32210366
J Biol Chem. 2005 Jun 10;280(23):22278-86
pubmed: 15817462
Platelets. 2017 Jun;28(4):333-341
pubmed: 27256961
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Eur J Cell Biol. 2011 Jun-Jul;90(6-7):527-35
pubmed: 21194787
Biochim Biophys Acta Mol Cell Res. 2019 Oct;1866(10):1567-1583
pubmed: 31330158
EMBO J. 2018 Aug 1;37(15):
pubmed: 29976761
Comb Chem High Throughput Screen. 2005 Mar;8(2):161-71
pubmed: 15777180
Mol Biol Cell. 2009 Mar;20(6):1785-94
pubmed: 19158376
Acta Virol. 2013;57(2):257-64
pubmed: 23600882
Nat Rev Cancer. 2017 Jan;17(1):38-53
pubmed: 27932800
Oncogene. 2012 Aug 2;31(31):3621-34
pubmed: 22105359
Int J Mol Sci. 2020 Jun 16;21(12):
pubmed: 32560271
EMBO J. 2003 May 15;22(10):2411-21
pubmed: 12743035
Cancer Res. 2011 Dec 15;71(24):7433-41
pubmed: 22006996
PLoS One. 2011;6(8):e22312
pubmed: 21876729
Int J Oncol. 2004 Apr;24(4):995-1004
pubmed: 15010840
FASEB J. 2005 Sep;19(11):1522-4
pubmed: 15972296
Oncol Rep. 2013 Mar;29(3):1147-53
pubmed: 23291973
J Biol Chem. 2012 Jan 27;287(5):3392-402
pubmed: 22170054
Anat Rec (Hoboken). 2010 Jun;293(6):925-37
pubmed: 20503387
Semin Cell Dev Biol. 2009 Apr;20(2):164-74
pubmed: 18951988
Bioinformatics. 2005 Jul 1;21(13):2933-42
pubmed: 15860560
Nucleic Acids Res. 1995 Dec 11;23(23):4878-84
pubmed: 8532532
FASEB J. 2014 Feb;28(2):978-97
pubmed: 24165480
Brain Res Bull. 2016 Sep;126(Pt 2):154-169
pubmed: 27060611
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5578-83
pubmed: 21415364
Cancer Res. 2009 Jan 1;69(1):358-68
pubmed: 19118021
BMC Biol. 2022 Jul 15;20(1):163
pubmed: 35840963
FEBS Lett. 2004 Nov 19;577(3):439-45
pubmed: 15556624
Cell Mol Life Sci. 2021 Jan;78(2):715-732
pubmed: 32372373
BMC Cancer. 2016 Mar 19;16:239
pubmed: 26993100
Br J Cancer. 2000 Jun;82(11):1808-13
pubmed: 10839295
Oncotarget. 2018 Jun 15;9(46):27940-27957
pubmed: 29963253
J Proteome Res. 2014 Apr 4;13(4):2205-14
pubmed: 24635658
Sci Rep. 2015 Sep 04;5:13605
pubmed: 26337752
J Exp Clin Cancer Res. 2009 Sep 22;28:129
pubmed: 19772640
Front Physiol. 2013 Oct 01;4:271
pubmed: 24101905
Br J Cancer. 2005 Nov 28;93(11):1267-76
pubmed: 16278664
Cancer Metab. 2022 Feb 2;10(1):3
pubmed: 35109923
Nat Rev Cancer. 2008 Dec;8(12):929-41
pubmed: 19005493
Front Oncol. 2020 Sep 02;10:1462
pubmed: 32983978
J Enzyme Inhib Med Chem. 2016;31(3):345-60
pubmed: 26619898
Carcinogenesis. 2011 Nov;32(11):1713-23
pubmed: 21880579
Br J Cancer. 2020 Jan;122(2):157-167
pubmed: 31819195
J Immunol Methods. 2003 Nov;282(1-2):117-34
pubmed: 14604546